Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Pfizer : delays drug price hikes after talking with Trump

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 03:20am CEST
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

WASHINGTON/NEW YORK (Reuters) - Pfizer Inc said on Tuesday it was deferring drug price increases for no more than six months after the company's chief executive officer had an extensive conversation with U.S. President Donald Trump.

The rollback came a day after Trump took aim at Pfizer and other U.S. drugmakers for raising prices on some of their medicines, saying in a tweet that they "should be ashamed" and that his administration would respond.

Pfizer on Tuesday said it would defer price increases that went into effect on July 1 until the end of the year or until the president's drug pricing blueprint goes into effect - whichever is sooner. The company said it would return drug prices to their pre-July 1 levels as soon as technically possible.

On Tuesday, Trump said in a tweet that Pfizer had agreed to roll back drug price hikes after he and U.S. Health and Human Services Secretary Alex Azar spoke with the company's CEO, Ian Read.

"We applaud Pfizer for this decision and hope other companies do the same," Trump, who is traveling in Europe, said in a tweet.

Pfizer, one of the largest pharmaceutical companies, now likely will not raise drug prices until after the 2018 midterm elections in November. That gives Trump, who made lowering prescription drug prices a top 2016 presidential campaign issue, a short-term victory he can point to in the run-up to the elections, which are being closely watched to see if Trump's fellow Republicans will be able to maintain control of both the Senate and the House of Representatives.

Pfizer raised list prices on around 40 medicines earlier this month. Those include Viagra, cholesterol drug Lipitor and arthritis treatment Xeljanz, according to Wells Fargo. List prices do not include rebates and discounts drugmakers may offer.

The Trump administration has not yet taken significant action to lower drug prices. Azar has said lowering prices long term will take years because of the complexity of the healthcare system.

Trump rolled out a blueprint in May on how his administration planned to lower drug prices. Trump said in May that some drug companies would announce "voluntary, massive" price decreases in two weeks, though none have materialized yet.

Pharmaceutical company shares rose after Trump unveiled his drug pricing blueprint.

Azar praised Pfizer on Tuesday. "I commend Pfizer for its constructive and professional approach, and its desire to work with President Trump to be part of the solution and not part of the problem," he said in a statement.

(Reporting by Yasmeen Abutaleb and Michael Erman; Additional reporting by Eric Walsh; Editing by Lisa Shumaker and Leslie Adler)

By Yasmeen Abutaleb and Michael Erman

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
10:29aPFIZER : Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal..
AQ
09/20PFIZER : Studies from Pfizer Update Current Data on Kinase Inhibitors (Updates o..
AQ
09/20PFIZER : Trademark Application for "VIZIMPRO" Filed by Pfizer
AQ
09/20PFIZER : Studies from Pfizer Yield New Data on Immunoglobulins (Rational optimiz..
AQ
09/20PFIZER : Trademark Application for "FLAGYL" Filed by Pfizer
AQ
09/20PFIZER : U.S. Patents Awarded to Inventors in Connecticut (Sept. 20)
AQ
09/20PFIZER : U.S. Patents Awarded to Inventors in Massachusetts (Sept. 20)
AQ
09/20PFIZER : Research Results from Pfizer Update Understanding of HIV/AIDS (No Clini..
AQ
09/20Animal health firm Elanco surges 41 percent on debut
RE
09/20PFIZER : Trademark Application for "THE HEMLINE" Filed by Pfizer
AQ
More news
News from SeekingAlpha
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/20Entasis Therapeutics Readies $75 Million IPO Plan 
09/20FDA grants Breakthrough Therapy designation to Pfizer's PF-06482077 
09/19PFIZER AND CONATUS : Emricasan And NASH 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
Financials ($)
Sales 2018 54 227 M
EBIT 2018 20 582 M
Net income 2018 13 123 M
Debt 2018 24 897 M
Yield 2018 3,13%
P/E ratio 2018 19,50
P/E ratio 2019 17,99
EV / Sales 2018 5,19x
EV / Sales 2019 4,94x
Capitalization 256 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 42,4 $
Spread / Average Target -3,1%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER19.44%256 467
JOHNSON & JOHNSON0.53%380 898
NOVARTIS-0.56%216 108
ROCHE HOLDING LTD.-4.65%210 186
MERCK AND COMPANY25.79%188 241
AMGEN17.99%132 756